Shares of Ocera Therapeutics Inc. (NASDAQ:OCRX) traded up 10.2% on Friday . The stock traded as high as $2.42 and last traded at $2.26, with a volume of 58,725 shares. The stock had previously closed at $2.05.

Separately, Zacks Investment Research cut Ocera Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 7th.

The stock’s 50-day moving average price is $2.51 and its 200 day moving average price is $2.69. The firm’s market cap is $49.82 million.

Ocera Therapeutics (NASDAQ:OCRX) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.02. On average, analysts predict that Ocera Therapeutics Inc. will post ($1.34) earnings per share for the current fiscal year.

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.